News
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
19h
News Medical on MSNMonoclonal antibody can effectively reverse potentially bleeding complications linked to ticagrelorAn investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic bleeding complications linked to ticagrelor, a common drug used to treat patients ...
The FDA has granted approval to Akeso's differentiated programmed cell death protein 1 (PD-1) monoclonal antibody, penpulimab ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...
A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) ...
9h
Vietnam Investment Review on MSNFDA Approves Akeso s Penpulimab for Dual Use in Nasopharyngeal Cancer TreatmentAkeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) has approved its differentiated PD-1 monoclonal antibody, penpulimab-kcqx, in ...
During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...
1h
Emirates News Agency on MSNAbu Dhabi advances precision medicine for Alzheimer’s disease patientsAbu Dhabi has taken a groundbreaking step in personalised healthcare by integrating APOE genetic testing for Alzheimer’s ...
1h
Miami Community Newspapers on MSNHoly Cross Health Now Offers Bispecific Therapy for Cancer PatientsGroundbreaking treatment enhances the immune system's ability to fight cancer Holy Cross Health now offers bispecific therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results